JP2025111616A5 - - Google Patents

Info

Publication number
JP2025111616A5
JP2025111616A5 JP2025071172A JP2025071172A JP2025111616A5 JP 2025111616 A5 JP2025111616 A5 JP 2025111616A5 JP 2025071172 A JP2025071172 A JP 2025071172A JP 2025071172 A JP2025071172 A JP 2025071172A JP 2025111616 A5 JP2025111616 A5 JP 2025111616A5
Authority
JP
Japan
Prior art keywords
disorder
disease
compound
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025071172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025111616A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/098460 external-priority patent/WO2020259675A1/zh
Application filed filed Critical
Publication of JP2025111616A publication Critical patent/JP2025111616A/ja
Publication of JP2025111616A5 publication Critical patent/JP2025111616A5/ja
Pending legal-status Critical Current

Links

JP2025071172A 2019-06-28 2025-04-23 ニューロキニン－１アンタゴニスト Pending JP2025111616A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201910572272.1 2019-06-28
CN201910572272 2019-06-28
CN201911375262.5 2019-12-27
CN201911375262 2019-12-27
PCT/CN2020/098460 WO2020259675A1 (zh) 2019-06-28 2020-06-28 神经激肽-1拮抗剂
JP2021577929A JP7702887B2 (ja) 2019-06-28 2020-06-28 ニューロキニン－１アンタゴニスト

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021577929A Division JP7702887B2 (ja) 2019-06-28 2020-06-28 ニューロキニン－１アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2025111616A JP2025111616A (ja) 2025-07-30
JP2025111616A5 true JP2025111616A5 (https=) 2025-09-17

Family

ID=74059657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577929A Active JP7702887B2 (ja) 2019-06-28 2020-06-28 ニューロキニン－１アンタゴニスト
JP2025071172A Pending JP2025111616A (ja) 2019-06-28 2025-04-23 ニューロキニン－１アンタゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021577929A Active JP7702887B2 (ja) 2019-06-28 2020-06-28 ニューロキニン－１アンタゴニスト

Country Status (11)

Country Link
US (1) US12421260B2 (https=)
EP (1) EP3991730A4 (https=)
JP (2) JP7702887B2 (https=)
KR (1) KR102940508B1 (https=)
CN (2) CN113905735B (https=)
AU (1) AU2020308397B2 (https=)
BR (1) BR112021026554A2 (https=)
CA (1) CA3144247A1 (https=)
MX (1) MX2021015827A (https=)
TW (1) TWI853965B (https=)
WO (1) WO2020259675A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
CN114671913A (zh) * 2020-12-25 2022-06-28 上海盛迪医药有限公司 一种神经激肽-1拮抗剂的晶型及其制备方法
JP2025500688A (ja) * 2022-01-12 2025-01-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ニューロキニン－１アンタゴニストプロドラッグ化合物の医薬組成物
CN118475589A (zh) 2022-01-12 2024-08-09 江苏恒瑞医药股份有限公司 一种神经激肽-1拮抗剂前药化合物的晶型
CN119528985A (zh) 2023-08-28 2025-02-28 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
US5661162A (en) 1992-12-14 1997-08-26 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists
ES2120170T3 (es) 1994-01-13 1998-10-16 Merck Sharp & Dohme Antagonistas azaciclicos gem-disustituidos de taquiquininas.
WO1998022542A2 (en) * 1996-11-08 1998-05-28 Ikonos Corporation Chemical functionalization of surfaces
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
CN1678317B (zh) * 2002-07-03 2010-10-27 先灵公司 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽-1(nk-1)拮抗剂的1-酰氨基-4-苯基-4-苄氧基甲基-哌啶衍生物和相关化合物
AR046769A1 (es) * 2003-12-22 2005-12-21 Schering Corp Composiciones farmaceuticas
CN102573475B (zh) * 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
CA3123900A1 (en) * 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
CN102775401B (zh) 2012-08-15 2015-01-07 青岛农业大学 一种美洛昔康的合成方法
CN108148060B (zh) * 2016-12-05 2020-06-19 四川科伦博泰生物医药股份有限公司 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
CN107383008A (zh) * 2017-08-14 2017-11-24 苏州信恩医药科技有限公司 一种罗拉匹坦的合成方法

Similar Documents

Publication Publication Date Title
JP2025111616A5 (https=)
JP5046465B2 (ja) アリールアルキルアミンから誘導されるカルバメート
JP6298765B2 (ja) 脳卒中の治療または予防に使用されるするためのフェニルカルバメート化合物
CN1122018C (zh) 作为药用活性成分的6－二甲氨基甲基－1－苯基环己烷化合物
DE69906389T2 (de) Verfahren zur herstellung von citalopram
JP2011517443A5 (https=)
JP2021513975A5 (https=)
JP2004516278A (ja) 一酸化窒素合成酵素阻害物質であるリン酸塩
PT1028940E (pt) Processo para produzir oxazolidinonas
CN1383423A (zh) 6－氟双环[3.1.0]己烷衍生物
US20080064876A1 (en) Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP2015063529A (ja) アルホルモテロールの合成方法
US8563547B2 (en) (6,7-dihydro-2-nitro-5H-imidazol[2,1-b][1,3]oxazin-6-yl) amide compounds, preparation methods and uses thereof
WO2004113352A1 (en) Silylated heterocyclylurea derivatives as cytokine-inhibitors
JP2015516968A5 (https=)
JP2020510041A5 (https=)
JP5774694B2 (ja) フェニルカルバメート化合物およびこれを含む筋肉弛緩剤
JP2019537624A5 (https=)
JP2025506504A5 (https=)
US20220064111A1 (en) Enantioselective synthesis of brivaracetam and intermediates thereof
JP2008509896A (ja) 保護化アミノチアゾールのフッ素化方法
JPH10504820A (ja) Ｎ−置換されたフェノチアジン類の使用
JP2023511152A5 (https=)
JP2020507567A5 (https=)
KR20100074303A (ko) Ｏ-데스메틸벤라팍신 푸마레이트의 결정형